In vitro models, in vivo models, and pharmacokinetics: what can we learn from in vitro models?
about
Alternative strategies for proof-of-principle studies of antibacterial agentsSilver Nanoparticle-Mediated Cellular Responses in Various Cell Lines: An in Vitro ModelEffect of Predatory Bacteria on Human Cell LinesAntimicrobial breakpoints for gram-negative aerobic bacteria based on pharmacokinetic-pharmacodynamic models with Monte Carlo simulationExposure-response analyses of tigecycline efficacy in patients with complicated skin and skin-structure infections.Setting and revising antibacterial susceptibility breakpoints.Evaluating drug resistance in visceral leishmaniasis: the challenges.Experimental impact of aspirin exposure on rat intestinal bacteria, epithelial cells and cell line.In vitro pharmacokinetic and pharmacodynamic evaluation of S-013420 against Haemophilus influenzae and Streptococcus pneumoniae.Development of sustained-release antibacterial urinary biomaterials through using an antimicrobial as an organic modifier in polyurethane nanocomposites.Estimation of cefuroxime dosage using pharmacodynamic targets, MIC distributions, and minimization of a risk function.A novel in vitro pharmacokinetic/pharmacodynamic model based on two-compartment open model used to simulate serum drug concentration-time profiles.A novel in vitro metric predicts in vivo efficacy of inhaled silver-based antimicrobials in a murine Pseudomonas aeruginosa pneumonia model.
P2860
Q26850895-7524D7EF-212C-4191-8F11-A8C6664755A9Q28079043-9665D7D9-2501-45B2-AA44-1A9989B35797Q28553794-1485A713-4022-457C-B672-AB43A6053786Q34188814-4AEE9388-E8BB-4677-A024-F3A9E31A01BFQ35840772-812E6E1D-E76E-47C3-89C1-4C2C6C106454Q35913176-66D0332A-E12B-42DA-ADC9-743E983DCAD6Q39014583-D755F88A-2D04-4323-B3CF-656426B75EE6Q39737713-DFFB27DD-9298-42F3-B551-583D22CC15ACQ42111255-D87D560A-2ACF-4843-A282-59123584A8A2Q43657560-D38E404A-3578-43DA-A6A5-052E6097E941Q46272620-01935374-0D46-4D7A-AAC9-F170FADC175DQ51912208-1772C5DE-B903-462A-B96A-3143AE2F6169Q52568549-AAF81249-6550-41BD-BA20-7295603EDF3A
P2860
In vitro models, in vivo models, and pharmacokinetics: what can we learn from in vitro models?
description
2001 nî lūn-bûn
@nan
2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
In vitro models, in vivo model ...... we learn from in vitro models?
@ast
In vitro models, in vivo model ...... we learn from in vitro models?
@en
In vitro models, in vivo model ...... we learn from in vitro models?
@nl
type
label
In vitro models, in vivo model ...... we learn from in vitro models?
@ast
In vitro models, in vivo model ...... we learn from in vitro models?
@en
In vitro models, in vivo model ...... we learn from in vitro models?
@nl
prefLabel
In vitro models, in vivo model ...... we learn from in vitro models?
@ast
In vitro models, in vivo model ...... we learn from in vitro models?
@en
In vitro models, in vivo model ...... we learn from in vitro models?
@nl
P2093
P2860
P356
P1476
In vitro models, in vivo model ...... we learn from in vitro models?
@en
P2093
P2860
P304
P356
10.1086/321850
P407
P478
33 Suppl 3
P577
2001-09-01T00:00:00Z